Date
Attendees
Committee Member | Present | Absent |
---|---|---|
X | ||
X | ||
X | ||
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | X | |
X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
Agenda
Item | Who | Talking Points |
---|---|---|
Discussion of potential submission of FidoCure and Vidium Animal Health data |
| |
DGAB Updates | Recently Approved
ICDC Studies in Active Submission
| |
BPSC Updates |
| |
Upcoming Steering Committee Meeting |
| |
Next Software Release |
|
Minutes (Not Verbatim)
AL - Jerry Post agreed that it is an exciting time for canine oncology. He thinks it would be a good idea for us to connect more. He expressed some concerns with integrating their data with our committee. They have novel data that would be interesting for the ICDC. Vidium has a publication out and may be more willing to share data.
TH - We should schedule a formal session with both groups to reconnect.
TH - Debbie has been in touch and has a paper that has been accepted that actually uses ICDC data.
TH - Cancer health disparity in acral melanoma in African Americans. Human dog comparative oncology could be important.
AL - Will H. has a paper that performs a broad assessment of canine melanomas in dogs
JO - Did we want to find out if there is publicly available data on this and bring it into the ICDC?
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Action items
- Debbie to write invitation for Jaime Modiano
- Revisit new steering committee members in September
- Debbie Knapp to send an email to FidoCure and Vidium to see if these groups are willing to sit down and meet with us.